Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am confident in my convictions .....
Its been a bumpy road .......
but we are still moving forward .......
increased revenues in the last two quarters ......
patented ADMIXMAP ........(very important)
M&A with three other Labs .....
Product Time frame and Revenue expectations .....
I'll say it again .......
HOLD AND BUY THE DEALS --- GEO
Dnaowner .......
If I might add .......
I find his actions on this board .......
like walking across a cow pasture ......
you know where your headed ......
but ......
he ruins your boots on the way .......
don't step in it ......
WALK AROUND IT --- GEO
Stinkboy .......
Give it a rest pal ......
they could be working some where else .....
and making a TON more money .....
They are getting paid .....
but no where over paid .......
If you feel they are over paid ......
perhaps you should have extended your education ......
and then you could more easily understand .......
their worth, compared to their salary .....
Buy and hold Stinkboy .......
you will be better off for it long term .....
as well as the rest of us ........
on a scale of 1 to 3 ......
we are now in phase 2, moving towards 3 ........
I hope I kept it simple for you ......
So many doors .....
and we only need one to open right now ......
KNOCK KNOCK, COME IN --- GEO
less OS after the R/S ......
if you are indeed long .......
I/you are able to aquire a bigger percentage ......
of this FANTASTIC science .......
Time may or may not be limited .......
but lets be honest .......
When we have traction .....
and I'm pretty sure 2006 will be great .......
we will be on our way .........
The K report said $45 long term .......
1,2,3,5,10 yrs who knows .....
but a double a triple in the near future is nice ......
Companys are climbing on board .......
bringing science as well as patents .......
They feel comfortable for a reason .......
joining DNAG ......
Half empty half full? .....
IS IN THE EYES OF THE BEHOLDER --- GEO
Hopeless ......
I would like a phone number as well .....
as the name of the Company .........
The reason I ask is because last time ........
it was said we were over 180mil ......
and it was only SEPT, OCT .....
TY --- GEO
I'm trying to follow ....
our last M/A ........
Ellipsis has been in a working enviroment ......
with TTH on the Toronto exchange ....
TTH today released some Clinical results .....
an update on the ongoing exploratory Phase IIa clinical studies of its lead diabetes regenerative therapy ......
Price and Vol went up ......
Now the wierd thing is .....
They HALTED tradeing after the bell .....
maybe JUST maybe they have news on AZD-103 ......
That would be good .......
FINGERS CROSSED --- GEO
golf4uto ....
here are my thoughts ......
in general, we are holding .....
few deals available .......
We need a NR to understand ......
WHY we went to Dutchess .......
Long Term Hold ......
increase your position .....
if/when you can .......
less than 1% OS traded today (so far) .......
should see accumulation .......
from here on in ............
JMHO --- GEO
AZD-103 .....
http://www.ellipsisneuro.com/research/pipeline.html
http://www.transitiontherapeutics.com/technology/index.php?cm=2&cp=7
VERY INFORMATIVE LINKS --- GEO
wrl ...your welcome .. eom
OK Virgil I fixed it .....
Thanks ......
You're right I should watch my wording ......
but I promise you ......
I will use that PHRASE .....
maybe with the words " LOTS OF "
KEEP ON KEEPING ON VIRGIL HILTS
UNITED WE .....
DIVIDED WE ......
AH, YOU KNOW --- GEO
GCBR .....
That article you posted ......
was excellent regarding .....
personal medicine .......
and genome mapping ........
JMHO, we are closer than many realize .......
I really liked the mention of Harvard Medicine .....
When the public realizes what we can accomplish .....
regarding "SAFETY STANDARDS" with regards to medication ....
we will ..... ummm ..... EXPLODE
KEEP UP THE GOOD WORK ARCH and ANN --- GEO
Virgil Hilts .....
Thank You for your post and kind words .....
You said; ...
With all the acquisition activity, I find it hard imagine that they are in much danger of going belly up. Big revenues are potentially not that far away, and an announcement of impending big revenues could potentially come at any time. The potential gain to risk ratio seems to be getting higher all the time.
If you look at our VOL over the last 3 months ......
You will notice Accumulation ......
We have started a Bull Cycle .....
And in the last month even with a sell off ......
we are up over 50% in our SP .......
Revenue has increased Quarter over Quarter .......
We are making revenue NOW ......
WE ARE UNDERVALUED --- GEO
P.s HOLD AND BUY THE DEALS ....
66fan ...
Sorry about that ......
I didn't see worktoplays DD ......
and I have to agree with your comment .....
BUT 100% DD BY WORKTOPLAY --- GEO
We seem to involved in a WEB ......
of R/D ......
NICE TO SEE W2P, TY --- GEO
Nice DD GCBR TY ....eom
Nice DD 66fan TY ........eom
Revenues and Cost of Sales
During the three and nine months ended September 30, 2005 and 2004, revenues were $316,983 and $906,470 for 2005, respectively and $165,647 and $648,925 for 2004, respectively. A $151,336 increase in revenues for the third quarter from the prior period is a 91% increase while a $257,545 increase in revenues for the nine month period ending September 30, 2005 compared to the prior period is a 40% increase. In addition to the revenues recognized in the accompanying statement of operations, we also have recorded deferred revenues of $113,792 as of September 30, 2005. Deferred revenue resulted from some ANCESTRYbyDNA(TM) and EURO-DNA(TM) client testing that was not complete as of September 30, 2005. These amounts will be recognized as revenue in the fourth quarter of 2005.
The approximately $151,000 increase in revenues for the three months ended September 30, 2005 compared to the same period in the prior year is mainly the result of our ANCESTRYbyDNA(TM) revenues increasing by approximately $126,000, our paternity services increasing by approximately $10,000 and EURO-DNA(TM) revenues increasing approximately $31,000 compared to the same period in the prior year. These increases are due to our increased promotion and marketing of these services. We recorded approximately $16,000 of revenues from our mtDNA(TM) product, $11,000 of revenues from our DNAWitness-Mito(TM) and $10,000 of revenues from our Y-chromosome products which were added to our product line when we acquired Trace Genetics. This was offset by a decrease of approximately $60,000 from our genotyping services and $8,000 from our DNAWitness(TM) sales. In addition, we had approximately $15,000 of other revenues.
The approximately $258,000 increase in revenues for the nine months ended September 30, 2005 compared to the same period in the prior year is a result of our ANCESTRYbyDNA(TM) revenues increasing by approximately $136,000, our paternity services increasing by approximately $89,000 and our EURO-DNA(TM) revenues increasing approximately $74,000 compared to the same period in the prior year. These increases are due to our increased promotion and marketing of these services. We recorded approximately $16,000 of revenues from our mtDNA(TM) product, $11,000 of revenues from our DNAWitness-Mito(TM) and $10,000 of revenues from our Y-chromosome products which were added to our product line when we acquired Trace Genetics. This was offset by a decrease of approximately $78,000 from our genotyping services and $15,000 from our DNAWitness(TM) sales. In addition, we had approximately $15,000 of other revenues.
Paternity sales are generated primarily through our various distributors and from our website www.ancestrybydna.com. The majority of the increase in sales during 2005 compared to 2004 was from a distributor that was added during the second quarter of 2004. Paternity testing is an add-on service, and we expect revenues to continue to fluctuate in this market. While we have not yet implemented a formal marketing and sales plan for this service, we continue to perform market research and gather information in order to define and implement a formal marketing strategy. One distributor accounted for approximately $105,000 of our paternity sales during the first nine months of 2005. We do not expect these revenues to continue for the balance of the year and are working hard to replace the potential short-fall. During the third quarter and into the last quarter we will be accelerating our direct marketing and mail campaign for our ANCESTRYbyDNA(TM) and DNAWitness(TM) products and services as well as the Trace Genetics products and services.
Genotyping sales were generated primarily through work with universities with one university being our major client of this service. The decrease of genotyping services of approximately $60,000 during the third quarter of 2005 compared to the same period in 2004 and approximately $78,000 during the nine months ended September 30, 2005 compared to the same period in 2004 was the result of decreased service provided to one university. To date, our genotyping service customers have come to us either through client referrals or our general website. In the future, we plan to concentrate our genotyping services on specific diseases, including cancer, neurological disorders, and heart disease. By concentrating on specific diseases, we hope to develop an expertise that will attract customers in those areas requiring external assistance and additional research capacity. One university accounted for approximately $150,000 of our genotyping sales during the first nine months of 2005.
As part of our on-going genotyping contract services work for one of our new customers, we have offered to perform ANCESTRYbyDNA testing services on 284 children suffering from a disease known as ALL or Acute Lymphocyte Leukemia and anticipate under a joint publication agreement to submit a manuscript for publication during 2006. Following this early pre-screening, the ALL program will test nearly 3,000 children afflicted with this disease in hopes that we will be better able to help the research hospital determine the genetic markers that are inherited and that may play a role in disease formation, advancement or remission. Treatment protocols or treatment regimes include multiple drug therapies and include, Taxol and Taxol like derivatives as well as other chemotherapy treatments and protocols. It is too early to determine the potential benefits to us, but we believe that our donation of our technology and services is crucial to the development of better and improved treatments for ALL. Currently, nearly 10-20% of the children afflicted with this disorder do not survive beyond 18-24 months after diagnosis. We believe that our technology combined with the research hospital's other work and including the contracted genotyping work performed by us for them, may help in reducing this dreadful statistic.
We continue to market our DNAWitness(TM) product through marketing to various agencies, our attendance at trade shows and through our relationships with Lynn Peavey catalog, Orchid Biosciences, and ReliaGene Technologies. We continue to seek to develop other distributors of our services and products. During 2004, our products, DNAWitness(TM) 2.0, RETINOME, and EURO-Witness 1.0 were featured in the Lynn Peavey Company catalog and the Lynn Peavey Web site. We trained Lynn Peavey Company personnel to establish and conduct seminars and training programs for detectives, crime laboratory personnel and crime scene personnel on DNAWitness(TM). Similarly, we have trained nearly 2,000 forensic personnel that include detectives, prosecutors and forensic scientists about our technology and its use. We anticipate continuing to train personnel on the use of our technology and products throughout 2005. Because these are new products and there are no similar products being marketed, we believe that forensic revenues will continue to fluctuate as we continue to research the markets and refine our sales and marketing strategy for our products. We have identified and applied for several grants and submitted our technology for federal review for applications that include human identification and terrorist tracking. We have not experienced and do not anticipate any funding of our research and development or deployment of our technology into any of these applications in 2005. We believe that the restraint of our sales in the forensics market does not originate from a lack of desire to use the technology by the detective or the prosecutor but rather a lack of funding for the increased staff that will be required to review cold case files, open new investigations or identify missing persons from stored human remains. We believe that the bulk of our investigative support will come through local and regional police, fire and detective agencies that do not require any federal funding to use our services and technology. We will however, continue to pursue much larger applications for our technologies on a global basis and will participate in several forensic and biometric venues in the remainder of 2005 that offer us a broad platform exposure to the world market. We are also seeking distributors of our products and services on a global basis applying our technology wherever the need could arise.
During the third quarter of 2005 compared to the same period in 2004, our sales of ANCESTRYbyDNA(TM) increased approximately $126,000. This is due to increased awareness and interest in genealogy and increased advertising during the third quarter by us in several markets. During the nine months ended 2005 compared to the same period in 2004, our sales of ANCESTRYbyDNA(TM) increased by $136,000. When we introduced our ANCESTRYbyDNA(TM) 2.5 during 2004, we increased the pricing which has resulted in a lower volume of product sold, but at a higher margin. Also, the product is relatively new to the market, and we believe sales will continue to fluctuate from period to period until we can better determine through continued market research and time how and where to best market and sell . . .
WE ARE CREATING VALUE --- GEO
A little something something ......
also stated in 2004 ........
By DR Hector Gomez .......
‘We have identified several clinical projects at the Moffitt that are of keen commercial and social interest,’ said Dr. Hector J. Gomez, MD, PhD, Chairman of the BOD and Chief Medical Officer of DNAPrint genomics, Inc. ‘Each of these programs offers us the opportunity to advance cancer treatment in a significant way,’ he said. Recent (November 2003) FDA guidance regarding pharmacogenomics technologies promulgate that if markers are validated using well understood markers in legitimate clinical environments, genetic tests derived from those markers should be included in new drug applications.
SEVERAL CLINICAL PROJECTS --- GEO
goliath003 ........
go long and accumulate .......
I am doing that as well .......
I agree with your post 100% ........
personalized medicine is the future ......
and JMHO, DNAG will play a big part of it ........
we are almost into 2006 .......
and 2006 WILL bring VALUE to us as SHARE HOLDERS .......
I plan to take advantage NOW .......
WHILE THE GETTING IS GOOD --- GEO
Oh Jever .......
I know that ......
you can use the "number" of bashers here .....
to estimate the TRUE value of DNAG ......
its kind of an oxymoron approach to investing .....
but lets be honest ........
way undervalued .........
6 yrs of RD are coming to a close ......
we have the ADMIXMAP patent (yummy) .......
One TOP 50 Company was impressed .......
with some testing we did for them .......
One day we will know who they are .........
maybe Monday? .......
but probably not .........
we are going to generate close/over a BILLION $$$$$$ ......
in revenue .....
in the NEXT FIVE YEARS .......
Q1 and Q2 in 2006 .....
should present us revenue .......
I plan to ......
Tim Yeatman from Moffitt Cancer Center ......
has professed that ADMIXMAP .........
has profound potential .......
Interseting choice of words coming from .......
Moffits director of "New Cancer Care Program"
also revenue has been increasing ......
in the last few Qaurters
HOLD AND BUY THE DEALS --- GEO
JEVER000 ....
WHY THE EXTRA CIRCLE? --- GEO
Lets face the facts .......
DNAG is way undervalued .......
more an more new investors ......
people are understanding .......
both the importance ......
as well as the potential ........
any number of positive things ......
can amplify DNAG SP .......
so in the mean time and in between time .........
HOLD AND BUY THE DEALS --- GEO
Goooood one Chris .....
Made me laugh out loud ......
THANKS FOR MAKEING MY DAY --- GEO
DR Yeatman said .....Mar2004
With the newly signed agreement, both organizations have teamed to make an important stride towards their goal of enabling a more personalized, safe and effective modality of cancer treatment for our current generation of cancer patients.
A primary area of focus for the effort is colorectal cancer, long a primary research interest for Yeatman, a professor of surgery in the USF Department of Interdisciplinary Oncology. Approximately 50 percent of patients fail to respond to the current FDA-approved therapy for colon cancer. Given the poor prognosis associated when therapies fail to work, there is a dire need for tools capable of predicting response beforehand, Yeatman said.
Working Hand in Hand ......
DNAPrint genomics and Moffitt Cancer Center .....
Moffitt will contribute gene expression and proteomics data resources currently in development and DNAPrint will contribute its ADMIXMAP platform and SNP analysis for mapping the genetic determinants of variable drug response by harnessing the power of human population genetic structure.
Over all of the program areas, the collaboration will combine Moffitt oncologists, research scientists, mathematicians and software engineers with DNAPrint computer scientists, molecular biologists and population geneticists, and draw upon DNAPrint’s pharmaceutical, clinical and regulatory expertise. Moffitt will contribute gene expression and proteomics data resources currently in development and DNAPrint will contribute its ADMIXMAP platform and SNP analysis for mapping the genetic determinants of variable drug response by harnessing the power of human population genetic structure. ‘We have identified several clinical projects at the Moffitt that are of keen commercial and social interest,’ said Dr. Hector J. Gomez, MD, PhD, Chairman of the BOD and Chief Medical Officer of DNAPrint genomics, Inc. ‘Each of these programs offers us the opportunity to advance cancer treatment in a significant way,’ he said. Recent (November 2003) FDA guidance regarding pharmacogenomics technologies promulgate that if markers are validated using well understood markers in legitimate clinical environments, genetic tests derived from those markers should be included in new drug applications.
Moffitt sees thousands of cancer patients each year, and ranks with M.D. Anderson (Univ. Texas), Johns Hopkins (Baltimore, MD) and Fred Hutchinson (Seattle, WA) as among the nation’s busiest and most prestigious cancer research centers. The center has established a domestic and international network of collaborating physicians to build patient registries and implement cutting-edge methods for reducing, treating or preventing the onset of cancer diseases.
“Moffitt scientists and physicians were impressed with DNAPrint’s ADMIXMAP approach for using a populations’ structure as a fuel for mapping drug response gene variants. We recognized its profound potential for contributing to the enhancement of cancer treatment”, said Moffitt’s Dr. Timothy Yeatman.
THIS STARTED IN MARCH 2004 --- GEO
hmmmmmm ......
profound potential? .........
oh my what could that mean? ......
"Moffitt scientists and physicians were impressed with DNAPrint’s ADMIXMAP approach for using a populations’ structure as a fuel for mapping drug response gene variants. We recognized its profound potential for contributing to the enhancement of cancer treatment”, said Moffitt’s Dr. Timothy Yeatman.
AND RECOGNIZED, TO BOOT ....... I LOVE IT --- GEO
sorry to support the 'underdog' here but in my following the board a for several months (8) I find GCBRs comments some of the most insightful and balanced. I appreciate ann and chris doresy ifada ole vern gratli and all the other long term investors an asset to this board their dd ethics are awesome! but posts like DR FUD and other ultra negative posters have the same value as zero many of the posts are a waste of time---and few really help you to make 'wise' decisions.
HAVE A NICE DAY AND WAIT FOR AN ENTRY POINT, AVERAGE DOWN --- GEO
If you want to make a wise investment .....
Read This:
DNAG HAS NEAR TERM AND MID TERM PIPELINES ........
HOLD AND BUY THE DEALS, VERY IMPORTANT --- GEO
"Profound Potential" ......
As first posted by GCBR .....
and Highlighted by ifada ......
said Timothy Yeatman, associate director for translational research and TCC director for Moffitt Cancer Center and Research Institutes new total cancer care program.
Profound Potential .......
REGARDING THE APPLICATION OF ADMIXMAP ON CANCER PATIENTS
HOLD AND BUY THE DEALS --- GEO
GCBR ......
You might be suprised my friend ......
BUT "MANY" STAND BESIDE YOU --- GEO
I don't stand behind you GCBR ......
I STAND BESIDE YOU --- GEO
GCBR IFADA ..........
Timothy Yeatman .......
Admixmap ..........
Moffit .............
SHHHHH DON'T TELL FUD --- GEO
See the importance ....
DNAPrint genomics Receives Notice of Allowance for Patent for Processing Gene Sequence Data
SARASOTA, Fla., Oct. 27, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTCBB:DNAG), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data.
"Though we are all 99.9% identical at the level of our DNA, it is the 0.1% difference called polymorphism that accounts for our individuality," stated Tony N. Frudakis, Ph.D., DNAPrint's founder and Chief Scientific Officer. "The technology our patent application covers relates to methods useful for measuring polymorphisms in and around genes that are part of large gene families, a task that traditionally has been problematic for the molecular genetics community."
Geneticists use "molecular addresses" to query and study specific genes much like a postman uses a street address to find the recipient of a letter. The methods covered in the patent are useful when there are several genes with the same or substantially similar "sequence" addresses. Many of the genes that are involved in drug metabolism and response are members of large gene families.
This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint's unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs.
REALLY BIG NR --- GEO
Hold and Buy the Deals ........
Average down ......
increase exposure .......
WAY UNDER VALUED --- GEO
100% Bull Cycle .....
Way UNDER VALUED --- GEO
NEW Investors ......
are becoming aware ......
of DNAG ......
and are understanding ......
The potential value .......
THE DNAG STORY --- GEO
1.5% .......
thats it ........
1.5% of OS traded yesterday .......
allowing for a 11% decline ........
HOLD AND BUY THE DEALS --- GEO
NICKOFTIME .....
YOUR HOPELESS ....LOL --- GEO
GCBR .....
I Think DNAG is doing something about .......
The pack of BASHERS .........
But they are more than just bashers .......
They are organized ........
So JMHO .......
HOLD AND BUY THE DEALS ........
AVERAGE DOWN ......
INCREASE YOUR POSITION .......
We are worth so much more .......
and what will happen when we have #######? ......
So many doors can open to this investment .......
So much is going to happen ........
So much has happened .......
Take advantage when you can ........
WE ARE WAY UNDERVALUED --- GEO
Dr FUD .....
Only 3million Shares Traded today ......
The last trade brought our % of loss up .......
A lot of investors are HOLDING AND BUYING THE DEALS ......
They may also be AVERAGING DOWN ......
TAKE ADVANTAGE IF YOU CAN --- GEO
Lets Look Back and Forward ....
BACK .......
On June 30/2005 .....
DNAG borrowed monies from Dutchess ......
Transaction was reported July 07/2005 SEC ....
July 08/2005 DNAG bought 18% of Biofrontera ......
Transaction was reported July 13/2005 SEC ........
FORWARD ........
On Novemember 18/2005 ......
DNAG borrowed monies from Dutchess ......
Transaction was reported November 25/2005 SEC ....
Something may have been "completed" November 26/2005 .....
Transaction was reported DEC 01/2005 ........
JUST TRYING TO UNDERSTAND WHY/WHEN --- GEO